Biblio Discovery — Demo Discovery Service

6 hasil untuk "Muhammad Shaalan Beg"

Menampilkan 1–6 · 0,70 detik · RSS

  1. Artikel Jurnal

    Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

    Davendra P. S. Sohal; Mai Chi Duong; Syed Ameen Ahmad dkk.

    JAMA Oncology · 2021 · Inggris · OpenAlex Scopus

    Importance: Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial. Objective: To determine 2-year…

  2. Artikel Jurnal

    Surgical Outcome Results From SWOG S1505

    Syed Arif Ahmad; Mai Chi Duong; Davendra P. S. Sohal dkk.

    Annals of Surgery · 2020 · Inggris · OpenAlex Scopus

    OBJECTIVE: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel…

  3. Artikel Jurnal Teks lengkap

    Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

    David S. Hong; Yoon‐Koo Kang; Mitesh J. Borad dkk.

    British Journal of Cancer · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. METHODS: Adults with various solid tumours…

  4. Artikel Jurnal Teks lengkap

    Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Edward Dela Cruz Drilon; D. Ross Camidge; W. Marston Linehan dkk.

    New England Journal of Medicine · 2024 · Inggris · OpenAlex Scopus

    The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI…